A Phase 1 Clinical Study on the Safety and Tolerability of PD-1 Antibody SHR-1210 in Patients With Advanced Solid Tumors
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Camrelizumab (Primary)
- Indications Adenocarcinoma; Breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Jul 2022 Status changed from active, no longer recruiting to completed.
- 23 Oct 2019 Planned End Date changed from 1 Mar 2019 to 1 Oct 2019.
- 17 Jan 2019 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.